Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction
Authors:
- Laurens A. van KleefLKLaurens A. van Kleef
- Jesse PustjensJPJesse Pustjens
- Jörn M. SchattenbergJSJörn M. Schattenberg
- Adriaan G. HolleboomAHAdriaan G. Holleboom
- Maarten E. TushuizenMTMaarten E. Tushuizen
- Robert J. de KnegtRKRobert J. de Knegt
- M. Arfan IkramMIM. Arfan Ikram
- Harry L.A. JanssenHJHarry L.A. Janssen
- Sven M. FrancqueSFSven M. Francque
- Willem Pieter BrouwerWBWillem Pieter Brouwer
- 7 May 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 83 (3) , 591-602
Abstract
Background and Aims: Screening for liver disease in the general population requires accurate non-invasive tests (NITs). A head-to-head comparison of NITs for early detection of clinically relevant liver disease among the target population for screening is lacking. Aproach and Results: Among the meta-cohort (Rotterdam Study and National Health and Nutrition Examination Survey) with metabolic dysfunction aged 18–80 years, 10 NITs were investigated. The diagnostic accuracy for clinically relevant conditions [increased liver stiffness measurement (LSM), at-risk metabolic dysfunction–associated steatohepatitis, advanced fibrosis, or cirrhosis) was assessed. Subgroup analysis included stratification by age group and diabetes/obesity status. We analysed 11,404 participants. Metabolic dysfunction–associated fibrosis 5 (MAF-5) obtained the highest AUC for increased LSM (≥8 kPa: 0.80; ≥12 kPa: 0.87) and advanced fibrosis (AUC: 0.90). Fibrotic NASH index and MAF-5 performed best for detecting metabolic dysfunction–associated steatohepatitis (AUC: 0.93 and AUC: 0.92, p =ns) and SAFE for cirrhosis (AUC: 0.92). To obtain 80% sensitivity for LSM ≥8 kPa, the corresponding MAF-5 cut-off resulted in fewer referrals (42%) compared to fibrosis-4 index (77%) and higher specificity (62% vs. 24%); MAF-5 was also superior for detection of LSM ≥12 kPa and advanced fibrosis. Age-dependent scores yielded lower sensitivity among younger individuals, for example, by referring 20% of the population with the highest NIT scores, the fibrosis-4 index, steatosis-associated fibrosis estimator, NAFLD fibrosis score, FORNS, and Hepamet fibrosis score yielded <10% sensitivity for LSM ≥8 kPa among individuals aged 18–35 years, while fibrotic NASH index and MAF-5 obtained 40% and 71%. Conclusions: Of the 10 investigated NITs, MAF-5 discriminated best between all conditions except cirrhosis, for which the steatosis-associated fibrosis estimator yielded the highest accuracy. The performance of the fibrosis-4 index was poor, implying that referral pathways for significant liver disease in low-prevalence populations can be improved when more accurate NITs such as MAF-5 are employed.Keywords
This publication has 44 references indexed in Scilit:
- The Rotterdam Study. Design update and major findings between 2020 and 2024European Journal of Epidemiology, 2024
- Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US populationHepatology, 2023
- The steatosis‐associated fibrosis estimator (SAFE) score: A tool to detect low‐risk NAFLD in primary careHepatology, 2022
- Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced FibrosisClinical Gastroenterology and Hepatology, 2020
- Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver diseaseHepatology, 2014
- Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2009
- FIB-4Hepatology, 2007
- The NAFLD fibrosis scoreHepatology, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005